Status:
COMPLETED
Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Haloperidol in Healthy Humans
Lead Sponsor:
Leiden University Medical Center
Collaborating Sponsors:
Dutch Diabetes Research Foundation
Conditions:
Insulin Resistance
Dyslipidemia
Eligibility:
MALE
20-40 years
Phase:
NA
Brief Summary
We hypothesized that short-term treatment with haloperidol induces insulin resistance through a mechanistic route that is independent of weight gain. We therefore treated healthy non-obese men with ha...
Eligibility Criteria
Inclusion
- Healthy men
- 20 kg/m2 \< BMI \< 26 kg/m2
- Age 20-40 years
- FPG \< 6 mmol/L
Exclusion
- FPG \> 6 mmol/L
- BMI \> 26 kg/m2
- Psychiatric disorders and/or use of antipsychotic or antidepressants drugs at present or in the past.
- A positive family history of schizophrenia
- Any significant chronic disease
- Renal, hepatic or endocrine disease
- Use of medication known to influence lipolysis and/or glucose metabolism
- Total cholesterol \> 7mmol/L and/or triglycerides \> 2 mmol/L
- Recent weight changes or attempts to loose weight (\> 3 kg weight gain or loss, within the last 3 months)
- Difficulties to insert an intravenous catheter
- Smoking (current)
- Severe claustrophobia (ventilated hood)
- Recent blood donation (within the last 2 months)
- Recent participation in other research projects (within the last 3 months), participation in 2 or more projects in one year
- Extensive sporting activities (more than 10 hours of exercise per week)
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2005
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00625014
Start Date
March 1 2005
End Date
July 1 2005
Last Update
August 26 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Leiden University Medical Center
Leiden, Netherlands, 2300 RC